Search filters

List of works by Sundar Jagannath

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma ⬇️

scientific article published on August 18, 2011

A phase 2 study of bortezomib in relapsed, refractory myeloma

scientific article

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

scientific article

African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States

scientific article published on 23 September 2020

Association between race and treatment patterns and survival outcomes in multiple myeloma: A connect MM registry analysis

scientific article published on 24 July 2020

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

scientific article

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

scientific article published in March 2005

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

scientific article

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

scientific article

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

scientific article published on 03 February 2011

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

scientific article published on 03 February 2011

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

scientific article published on 03 February 2011

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

scientific article published on 16 November 2015

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

scientific article

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

scientific article published on 29 May 2018

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

scientific article published in March 2006

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

scientific article published on 29 March 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

scientific article published on August 2016

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

scientific article

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

scientific article

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

scientific article

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

scientific article published on 11 December 2013

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

scientific article published on 10 December 2021

Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.

scientific article published on 10 February 2012

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

scientific article published on 01 August 2019

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

scientific article published on 13 January 2014

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

scientific article

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

scientific article

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

scientific article

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

scientific article published on 18 October 2010

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

scientific article

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

scientific article

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

scientific article

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

scientific article published in July 2004

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

scientific article

Paulina is supported by:

About Paulina

Help